Global veterinary vaccines and medicines suppliers Zoetis says it has started accepting proposals for research grants on the formulation and design of innovative approaches for the control of parasitic diseases that affect pets and livestock.
The company works in fields that include the discovery, development, manufacturing and marketing of veterinary vaccines and medicines.
In a statement posted on its website, the company said the deadline for the submissions of proposals for innovative approaches meant to help protect dogs, cattle, sheep and poultry from parasitic diseases is 28 February 2018.
The research will also seek out ways of extending the efficacy of therapeutics through new formulations. Zoetis Head of Parasitology and Global Therapeutics Research Debra Woods said a minimum of US$25 000 and a maximum of US$150 000 will be paid to support selected proposals.
“At Zoetis, we are interested in advancing novel approaches to protect animals from parasitic diseases, to improve the health and productivity of livestock animals and to help companion animals live longer, healthier lives. Through this grant programme, we aim to energise investigation into anti-parasitic therapeutics research and advance science in this area of high need in animal health,” Woods said.
Specifically, the company is seeking research proposals to explore new approaches to protect cattle and sheep from endoparasites (worms) and control resistant nematodes and trematodes, as well as preventing cryptosporidiosis. Proposals in poultry are required to seek out new approaches to control of coccidiosis.
Further, the company is seeking proposals that seek to protect dogs from heartworm disease using novel biological or biopharmaceutical approaches to prevention, while developing diagnostic tools for early detection of infections.
The research projects are also expected to improve the understanding of the early stages of heartworm infection, including the mechanisms of its migration through body tissues to the heart. The winning proposals will be announced on 31 March 2018.